Seqirus targets senior population with new flu shot

HOLLY SPRINGS, N.C. - Seqirus has begun shipping FLUAD, the company announced Tuesday, for the 2016-2017 flu season since gaining approval from the Food and Drug Administration late November last year. FLUAD is the first and only adjuvanted seasonal influenza vaccine approved in the United States, and was specifically developed to help protect adults aged 65 and older from the flu.

“As the first vaccine of its kind approved in the U.S. for the adult population aged 65 and older, FLUAD represents an important new option for those at the highest risk for serious complications from the flu,” stated Brent MacGregor, SVP commercial operations. “At Seqirus, we are proud to further fulfill our mission of securing health for everyone, including those who need the greatest protection, by delivering the first shipment of FLUAD to our valued customers in the U.S. this year.”

FLUAD was first licensed for use in Italy in 1997. Now approved in more than 30 countries, including the U.S., 81 million doses of FLUAD have been distributed worldwide. This 2016-2017 flu season is the first year that FLUAD will be available in the U.S.